Two markets designed to cross, not to queue. Each climbs Trust → Connect → Structure, and moves on only after clearing the gate for each step.
The usual assumption is "win Korea, then go to the U.S." For this business, that order is not the best one.
A single-payer system: once reimbursed, the whole market opens. The right place to prove "this app actually works." Revenue, though, takes a long time.
Many buyers, and B2C subscription actually works. Medicare Advantage covers more than half of ESKD patients, and Apple Health Records needs no developer registration. Marketing costs are high.
Advancing before the gate is cleared is the most common way startups die.
| Phase 1 — TrustSep 2026 – Aug 2027 | Phase 2 — ConnectSep 2027 – Dec 2028 | Phase 3 — Structure2029 – | |
|---|---|---|---|
| Koreapolicy door | Patients own their data MVP web app, pre-visit report · 30 → 100 pre-dialysis stage 3–4 patients · free, government grantsGate · 4-week retention, and repeated cases of patients bringing the report into the visit |
Patients connect to institutions Caregiver mirroring, care food, pharma pilots · 3,000 → 10,000 patients · commerce + pharma programsGate · first revenue, one hospital pilot sustained for a year |
Management becomes policy A nephrology clinic tool · hospitals and NHIS · hospital sales, reimbursement long-termGate · clinical evidence on delayed dialysis or surrogate endpoints |
| U.S.payer door | Asian-American beachhead Bilingual, Asian diets, Apple Health Records · Korean and Asian-American CKD patients · free, retention onlyGate · retention comparable to Korean users |
Take the pre-dialysis segment Head-on with "labs + trend + report" · stage 3–4, the competitors' blind spot · subscriptionGate · LTV/CAC holds |
Move inside the payer Engagement layer for value-based kidney care · Medicare Advantage plans and partners · enterprise contracts, free for patientsGate · one paid pilot with a partner |
The realistic form of U.S. Phase 3 may be an acquisition. U.S. kidney-care companies source patient-engagement technology through M&A and partnership rather than building it (Healthmap's acquisition of Carium, 2025). That is a designed exit, not a failure.
What "connecting to institutions" actually looks like.
Built first and hardest. One advising physician takes months, but that one makes the next ten easier.
Where a patient's day actually changes, and where first revenue appears. It is lifestyle, not medicine, so the regulatory load is lowest.
Opens last, but when it opens it is the whole market. Data and evidence from the two layers below are the only ticket in.
In Korea, no chronic-disease app has made money from B2C subscriptions. Revenue came from three places: commerce, B2B sales, and reimbursement. The app was the gateway; the money came from elsewhere.
Low-potassium, low-phosphorus, low-protein foods are essential for kidney patients and hard to find. The records become purchase signals.
Adherence drives outcomes for SGLT2 inhibitors, finerenone, and phosphate binders. Pharma already spends this budget.
The One-Pager also saves clinician time. Long-term, it is the basis for reimbursement.
₩11.9B revenue in 2024, still loss-making. Combined with CHA Bio Group in 2025.
Shut down in 2025. Users came; paid conversion never did.
3.4% of Korea's digital-health revenue. Medical devices take 41.3%.
There is no charge for the patient's record-keeping. The cost is carried by the three parties who help the patient: clinics, communities and family. The structure below is a second-half 2026 design; clinic and community pricing is set by agreement.
The clinic subscribes as a patient service and patients join free with an invitation code. When the patient allows it, the One-Pager reaches the clinic's screen. A flat monthly fee by patient band, independent of headcount changes.
The community subscribes and distributes to residents: a move-in kit (invitation code), a monthly logging class, family connection, and the One-Pager for partner clinics. The community receives anonymous participation statistics only; items under five people are not shown.
A subscription for the people beside the patient. Basic (free) · Supporter (1) · Family (3) · Family Plus (5). With a clinic or community pass, one supporter is included and higher plans pay only the difference.
Record-keeping is never locked
Family sees only what the patient allows
Clinics and communities too; communities get anonymous statistics only
Institutional fees are flat by band, not per head
No screen makes a judgment
Write to hello@kidneybloom.com with the type of institution (nephrology or dialysis clinic / senior residence or retirement community) and its size, and we advise on the matching plan band and trial terms. Confidential materials follow an NDA.
Clinics start on the Lite (clinical · demo) plan; communities on a 12-week free trial. We provide invitation codes and materials (move-in kit, QR), and run a monthly logging class with communities.
After reviewing the trial together, a one-year contract at the flat monthly fee for the band. Patients and residents start by entering the invitation code in the app, with no separate payment. The institution sees only what the patient allows (anonymous statistics only, for communities).
Design demos (fictional data): clinic screen · community screen · the patient's pass and family screen. Applicable medical, privacy and e-commerce regulations are confirmed through legal review.
Before incorporation, the first year runs on government startup programs rather than equity. Korea's pre-startup package is open only to applicants without a business registration, so the timing of incorporation is itself a strategic variable.
| Product | Brand · Patients | Entity · Funding | Regulatory · Medical | |
|---|---|---|---|---|
| Phase 1 Sep – Nov 2026 Build evidence | MVP web app live 10–30 patients in real use | Instagram carousels Seed a patient community | Defer registration Draft pre-startup application | MFDS pre-review request Consent architecture |
| Phase 2 Dec 2026 – Feb 2027 Enter the track | v2 from feedback Retention and logging metrics | 1–2 advising nephrologists 20 patient interviews | Apply to pre-startup package Women-founder track | Ministry interpretation Data-flow diagram |
| Phase 3 Mar – May 2027 Incorporate | Native app iOS · Android | 100 patients First B2B conversations | Incorporate on selection Women-owned certification | Seoul Bio Hub application Privacy operations |
| Phase 4 Jun – Aug 2027 Revenue experiments | B2B admin console Hospital pilot build | Self-sustaining community Patient stories | Prepare early-startup package Approach TIPS operators | Pharma PSP outreach U.S. entry groundwork |
Instead of projected revenue, we define five values to check once real-user data exists. No valuation talk without metrics.
Cost to acquire one patient
Share of users who can read their numbers
A chronic condition, a lasting record
Actual conversion in Lanes A and B
Surrogate endpoints and savings signals